Edmond DE Rothschild Holding S.A. bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,000 shares of the company’s stock, valued at approximately $892,000.
Other institutional investors have also recently made changes to their positions in the company. ABS Investment Management LLC purchased a new position in shares of Guardant Health in the 2nd quarter worth approximately $345,069,000. MCF Advisors LLC raised its holdings in Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after buying an additional 151 shares during the period. NFSG Corp purchased a new stake in Guardant Health during the 3rd quarter valued at $33,000. Jacobi Capital Management LLC bought a new stake in Guardant Health in the third quarter worth $35,000. Finally, Fulcrum Asset Management LLP bought a new stake in Guardant Health in the third quarter worth $37,000. Institutional investors own 92.60% of the company’s stock.
Guardant Health Stock Up 0.2%
Shares of Guardant Health stock opened at $145.83 on Friday. The stock’s fifty day moving average is $167.08 and its two-hundred day moving average is $133.80. Guardant Health, Inc. has a 52 week low of $74.55 and a 52 week high of $191.05. The company has a market capitalization of $19.73 billion, a PE ratio of -39.63 and a beta of 1.67.
Analyst Upgrades and Downgrades
GH has been the subject of several recent analyst reports. Royal Bank Of Canada lifted their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Stephens reissued an “overweight” rating and issued a $210.00 target price on shares of Guardant Health in a research note on Friday. Mizuho raised their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Piper Sandler cut their price target on shares of Guardant Health from $193.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $191.48.
Check Out Our Latest Stock Analysis on Guardant Health
Top Guardant Health Stories
Here are a few of the latest stories about GH:
- Positive Sentiment: Stephens reaffirmed its “overweight” rating and set a $210 price target, signaling confidence in the stock’s prospects. Stephens stock recommendations
- Positive Sentiment: A recent report focused on raised guidance, which may bolster expectations for the company’s business outlook. What raised guidance means for shareholders
- Neutral Sentiment: Insider Terilyn Monroe sold 3,842 shares, reducing her stake by about 15%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less clear-cut signal about the insider’s view of the company. Insider share sale
Insider Activity at Guardant Health
In related news, CTO Darya Chudova sold 7,738 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer owned 70,635 shares of the company’s stock, valued at $12,573,030. This trade represents a 9.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Terilyn Monroe sold 3,842 shares of Guardant Health stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $142.41, for a total transaction of $547,139.22. Following the sale, the insider owned 21,058 shares of the company’s stock, valued at $2,998,869.78. The trade was a 15.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 19,566 shares of company stock worth $3,320,185. 5.60% of the stock is currently owned by corporate insiders.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Recommended Stories
- Five stocks we like better than Guardant Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
